afety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines.Aesthet Surg J.2024;44(12):1330-1340. doi: 10.1093/asj/sjae131.

Ablon G, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-2 phase 3 trial.Toxicon. 2024;237(1):107353. doi: 10.1026/j.toxicon.2024.107353.

Relfydess®. EU Summary of Product Characteristics.

Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.

Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.








Contac
=*=*=*=*=*=
当前为第19/20页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页